论文部分内容阅读
选择80例我院在2014年3月至2015年3月期间确诊为2型糖尿病的患者,随机分为2组(对照组和观察组),每组40例。设置观察组为联合使用甘精胰岛素和瑞格列奈治疗2型糖尿病,设置对照组为通过皮下注射胰岛素治疗2型糖尿病,分析比较两组患者在治疗后的临床疗效。结果应用两种治疗方案均能使Hb A1c、2 h PG、FPG的水平在治疗后显著低于治疗前的水平,并且对照组在治疗后的Hb A1c、2 h PG、FPG水平均显著高于观察组,具有统计学显著性差异(P<0.05)。对照组在治疗后的总有效率达77.5%,显著低于观察组97.5%,具有统计学显著性差异(P<0.05)。结论联合使用甘精胰岛素和瑞格列奈治疗2型糖尿病具有维持血糖水平稳定性的临床效果,降低了患者对胰岛素的依赖,是一种值得大范围推广和应用的临床治疗方案。
Eighty patients with type 2 diabetes diagnosed in our hospital from March 2014 to March 2015 were randomly divided into 2 groups (control group and observation group), 40 cases in each group. Patients in observation group were treated with insulin glargine and repaglinide for type 2 diabetes mellitus. The control group was treated with subcutaneous insulin injection to treat type 2 diabetes mellitus. The clinical efficacy of the two groups was compared and analyzed. Results The levels of Hb A1c, 2 h PG and FPG after treatment were significantly lower than those before treatment, and the levels of Hb A1c, 2 h PG and FPG in the control group were significantly higher than those before treatment The observation group had a statistically significant difference (P <0.05). The total effective rate of the control group after treatment was 77.5%, which was significantly lower than that of the observation group (97.5%), with a statistically significant difference (P <0.05). Conclusions The combination of insulin glargine and repaglinide in the treatment of type 2 diabetes has the clinical effect of maintaining the stability of blood glucose level and reducing the patient’s dependence on insulin. It is a clinical treatment scheme worthy of wide application and promotion.